Director, Translational Sciences, Valius Sciences Previously ArsenalBio | PhD @UofT Science | Clinical Trials | Sports | Capital Markets 🚀
San Francisco
Joined August 2026
- Tweets98
- Following53
- Followers24
- Likes52
Stanley Zhou retweeted
#ESMO26 | OptiTROP-Breast01 – Final OS
In metastatic TNBC, sacituzumab tirumotecan improved median OS from 9.9 to 14.7 months vs chemotherapy (HR 0.60).
30-month OS: 26.8% vs 13.2%.
The survival benefit was maintained with longer follow-up. However, the lack of direct comparisons with existing ADCs leaves its place in treatment sequencing uncertain.
Stanley Zhou retweeted
#daraxonrasib clinical outcomes by allele in #RASolute302 from FDA NDA review.
These data perpetuate unresolved questions:
- is RASi as effective for KRAS WT; K12R? See Table 24; Fig 11.
- is 300 mg necessary for maximal clinical benefit? no data provided comparing 200 vs 300.
Stanley Zhou retweeted
Our new work using virus-specific T cells as biosensors in Long COVID. These data point to viral persistence detected by T cells and some level of T cell exhaustion. Excellent work by @markmpainter biorxiv.org/content/10.64898…
Prettyyyyy cool!
Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial
nature.com/articles/s41591-0…
Stanley Zhou retweeted
Dan Campbell gave a game ball to Dan Miller after the Lions beat the Cardinals.
Miller, the voice of the Lions, lost his wife to cancer this week.
Jared Goff (@JaredGoff16) needs to be in the MVP conversation.
4 Total TDs today, and the 0 INT carries on - come on now, unreal.
@Lions #NFL @NFLonFOX
Stanley Zhou retweeted
ICYMI 💥: @FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy with a simultaneous approval of the Guardant360 CDx assay
Full details 📰: hubs.li/Q04zRmm90
#oncology #bcsm
Stanley Zhou retweeted
New @jclinicalinvest study led by @BraunMDPhD @YaleCancer and super star Dr Madsen : HIF-2α inhibition with belzutifan preserves T-cell effector function in ccRCC—supporting the rationale for combining HIF-2α and PD-1 blockade without compromising T-cell activity.
Reassuring translational evidence!
jci.org/articles/view/204613
Stanley Zhou retweeted
ADC drug development is accelerating. But is biomarker science keeping pace?
Nearly 50% of ADC trials require no biomarker, while most that do still rely on conventional IHC.
In our new @NatRevClinOncol review published just in time pre-#ESMO26, we propose a modular framework to bridge this gap - moving beyond target expression to the multiple biological determinants of ADC efficacy and toxicity.
Proud to lead this international effort with @BarbaraPistill2 @nedmcnamee @rreddel @VivekSubbiah and colleagues.
🔗: nature.com/articles/s41571-0…
The CAR T field continues to slide with @CaribouBio news yesterday.
So unfortunate, and hope those affected will get new opportunities shortly.
#CART
Two FDA breakthrough designations for AbbVie's c-Met ADC Temab-A: refractory CRC with bevacizumab, and previously treated c-Met-expressing NSCLC. Nice momentum for the program. Still investigational, not two approvals. #ADC #Oncology
news.abbvie.com/2026-10-07-A…
Stanley Zhou retweeted
BREAKING: The U.S. government, Google, Meta & Zuckerberg-backed @biohub are launching a $1.8B push to build the data layer for AI biology.
The goal is to create the largest open, AI-ready biological dataset ever assembled, giving models the data needed to better predict how biology works & ultimately help treat disease.
The coalition is massive:
› Biohub committed $500M
› DOE is investing $500M+ across measurement, modeling & compute
› NIH is bringing $500M+ of federally funded datasets & repositories
› Meta, Google DeepMind & @IsomorphicLabs are jointly investing another $300M
This is effectively an infrastructure buildout for AI biology.
Instead of just building bigger models, they’re attacking one of the biggest bottlenecks in biology AI today, generating standardized, high-quality biological data at massive scale & making it openly available to researchers.
$1.8B committed to turning biology into something AI can increasingly model, predict & engineer.
LONESTAR didn't find a significant OS or PFS benefit from adding local radiation/surgery. Sometimes the extra treatment just doesn't pay off. #NSCLC #Oncology
ilcn.org/findings-call-into-…
